Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.56 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4238438 | 0.86 | BACE1 (0.46) | BACE1BACE2ADAM17LMNAMMP13 | |
| SCHEMBL4238523 | 0.80 | BACE1 (0.43) | BACE1BACE2CYP3A4CYP2C9LMNA | |
| SCHEMBL4233664 | 0.78 | BACE1 (0.46) | BACE1BACE2LMNAALDH1A1MAPT | |
| SCHEMBL4239036 | 0.72 | BACE1 (1.00) | BACE1BACE2CYP2C9LMNAGLA | |
| SCHEMBL8237931 | 0.71 | BACE1 (0.59) | BACE1BACE2RENAPP | |
| SCHEMBL15956555 | 0.68 | APP (0.53) | BACE1APP | |
| SCHEMBL4142705 | 0.66 | BACE1 (0.58) | BACE1BACE2CYP3A4CYP2C9LMNA | |
| SCHEMBL14258083 | 0.66 | BACE1 (0.41) | BACE1BACE2LMNAKMT2ACYP2C19 | |
| SCHEMBL8235054 | 0.66 | BACE1 (0.83) | BACE1BACE2CYP2C9LMNAGLA | |
| SCHEMBL5180824 | 0.65 | ADAM17 (0.79) | CYP3A4ADAM17CYP2C9BLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176850-A1 | Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | claimed |
| CN-101360716-A | Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer s disease, neurodegeneration and dementia | ASTRAZENECA AB (SE) | 2009-02-04 | — | — | CN | claimed |
| EP-1954682-A1 | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER S DISEASE, NEURODEGENERATION AND DEMENTIA | Astra Zeneca AB (SE) | 2008-08-13 | — | — | EP | claimed |
| WO-2007058601-A1 | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | claimed |
| US-20090176850-A1 | Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
| CN-101360716-A | Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer s disease, neurodegeneration and dementia | ASTRAZENECA AB (SE) | 2009-02-04 | — | — | CN | disclosed |
| EP-1954682-A1 | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER S DISEASE, NEURODEGENERATION AND DEMENTIA | Astra Zeneca AB (SE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007058601-A1 | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176850-A1 | Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia | PSEN2, MAPT, PSEN1 | BACE1 7/4885BACE2 26/4885CYP3A4 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.